U.S., Feb. 18 -- ClinicalTrials.gov registry received information related to the study (NCT07412704) titled 'A Study of BMS-986528 in Participants With Refractory Rheumatoid Arthritis' on Feb. 09.
Brief Summary: The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and the preliminary evidence of disease-modifying effect of BMS-986528 in participants with refractory, difficult-to-treat rheumatoid arthritis (RA).
Study Start Date: May 28, 2026
Study Type: INTERVENTIONAL
Condition:
Arthritis, Rheumatoid
Intervention:
DRUG: BMS-986528
Specified dose on specified days
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Bristol-Myers Squibb
Published by HT Digital Content Services...